CD20 Monoclonal Antibody (QCH6A7), PE, eBioscience™, Invitrogen™
Manufacturer: Invitrogen
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | 12-020-382-Each-of-1 | In Stock | ₹ 30,527.00 |
12-020-382 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 30,527.00
GST (18%): ₹ 5,494.86
Total Price: ₹ 36,021.86
Antigen
CD20
Classification
Monoclonal
Concentration
0.2 mg/mL
Formulation
PBS with 0.09% sodium azide; pH 7.2
Gene Accession No.
P19437
Gene Symbols
Ms4a1
Purification Method
Affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
12482
Content And Storage
4° C, store in dark, DO NOT FREEZE!
Form
Liquid
Applications
Flow Cytometry
Clone
QCH6A7
Conjugate
PE
Gene
Ms4a1
Gene Alias
AA960661; APY; ATOPY; B1; B-cell differentiation antigen Ly-44; B-lymphocyte antigen CD20; B-lymphocyte cell-surface antigen B1; B-lymphocyte surface antigen B1; Bp35; Cd20; CD20 antigen; CD20 cell surface protein; CD20 receptor; CVID5; EGK_06167; Fc epsilon receptor I beta chain; Fc Fragment of IgE high affinity I receptor for beta polypeptide; FCER1B; High affinity immunoglobulin epsilon receptor subunit beta; IgE Fc receptor subunit beta; IGEL; IGER; IGHER; LEU16; LEU-16; Leukocyte surface antigen Leu-16; Ly44; Ly-44; Lymphocyte antigen 44; membrane spanning 4-domains A1; membrane-spanning 4-domains subfamily A member 1; membrane-spanning 4-domains, subfamily A, member 1; membrane-spanning 4-domains, subfamily A, member 2; MGC3969; MS4A1; MS4A2; S7
Host Species
Rat
Quantity
100 μg
Primary or Secondary
Primary
Target Species
Mouse
Product Type
Antibody
Isotype
IgG2a κ
Related Products
Description
- The MAb QCH6A7 reacts with mouse CD20
- CD20 is a B cell specific, 32-kDa membrane protein that is expressed on late pro-B cells through memory B cells in the B cell lineage
- CD20 is not found on hematopoietic stem cells, early pro-B cells or later mature plasma cells
- CD20 is involved in intracellular calcium regulation and plays a role in B cell proliferation
- CD20 is intially expressed after the induction of CD19 during development and is coexpressed with IgM during the pre-B to immature B cell transition in bone marrow
- Expression of CD20 increases during maturation with almost all mature B cells expressing some level of CD20
- Unlike other B cell antigens, CD20 is not shed or internalized upon antibody binding
- Monoclonal antibodies against the CD20 antigen may be used to deplete B cells and CD20 has proven to be an effective immunotheraputic target in B cell lymphomas and several autoimmune diseases including rheumatoid arthritis and type I diabetes
- CD20 consists of 4 transmembrane domains and a 44 amino acid extracellular domain which contains the QCH6A7 epitope
- Staining with clone QCH6A7 provides significantly improved staining intensity compared to clone AISB12 in flow cytometric assays
- CD20 is a non-glycosylated surface phosphoprotein that has a molecular weight range of 33-37 kDa depending on the degree of phosphorylation
- CD20 is expressed on mature and most malignant B cells, in a subpopulation of T lymphocytes and follicular dendritic cells
- CD20 expression on B cells is synchronous with the expression of surface IgM and it regulates transmembrane calcium conductance, cell cycle progression and B-cell proliferation
- CD20 is also associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change, and/or BCR (B cell antigen receptor) aggregation
- After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface
- CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following monoclonal antibody treatment
- Diseases associated with CD20 dysfunction include Ms4a1-related common variable immune deficiency.